ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Drugs for Metabolic Disorders - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-34X2553
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
COVID 19 Impact on Drugs for Metabolic Disorders Market Global Research Reports 2020 2021
BUY CHAPTERS

Drugs for Metabolic Disorders - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-34X2553
Report
September 2024
Pages:117
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
Kowa
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma

Drugs for Metabolic Disorders - Market Size

The global market for Drugs for Metabolic Disorders was estimated to be worth US$ 82150 million in 2023 and is forecast to a readjusted size of US$ 160970 million by 2030 with a CAGR of 10.1% during the forecast period 2024-2030

Drugs for Metabolic Disorders - Market

Drugs for Metabolic Disorders - Market

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Metabolic Disorders, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Drugs for Metabolic Disorders by region & country, by Type, and by Application.
The Drugs for Metabolic Disorders market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Metabolic Disorders.
Market Segmentation

Scope of Drugs for Metabolic Disorders - Market Report

Report Metric Details
Report Name Drugs for Metabolic Disorders - Market
Forecasted market size in 2030 US$ 160970 million
CAGR 10.1%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
  • Hospital
  • Retail Pharmacy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Drugs for Metabolic Disorders manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Drugs for Metabolic Disorders in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Drugs for Metabolic Disorders in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Drugs for Metabolic Disorders - Market size in 2030?

Ans: The Drugs for Metabolic Disorders - Market size in 2030 will be US$ 160970 million.

Who are the main players in the Drugs for Metabolic Disorders - Market report?

Ans: The main players in the Drugs for Metabolic Disorders - Market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma

What are the Application segmentation covered in the Drugs for Metabolic Disorders - Market report?

Ans: The Applications covered in the Drugs for Metabolic Disorders - Market report are Hospital, Retail Pharmacy

What are the Type segmentation covered in the Drugs for Metabolic Disorders - Market report?

Ans: The Types covered in the Drugs for Metabolic Disorders - Market report are Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug, Other

Recommended Reports

Metabolic Disease Drugs

Endocrine Disorders

Metabolic Adjacent Drugs

1 Market Overview
1.1 Drugs for Metabolic Disorders Product Introduction
1.2 Global Drugs for Metabolic Disorders Market Size Forecast
1.2.1 Global Drugs for Metabolic Disorders Sales Value (2019-2030)
1.2.2 Global Drugs for Metabolic Disorders Sales Volume (2019-2030)
1.2.3 Global Drugs for Metabolic Disorders Sales Price (2019-2030)
1.3 Drugs for Metabolic Disorders Market Trends & Drivers
1.3.1 Drugs for Metabolic Disorders Industry Trends
1.3.2 Drugs for Metabolic Disorders Market Drivers & Opportunity
1.3.3 Drugs for Metabolic Disorders Market Challenges
1.3.4 Drugs for Metabolic Disorders Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drugs for Metabolic Disorders Players Revenue Ranking (2023)
2.2 Global Drugs for Metabolic Disorders Revenue by Company (2019-2024)
2.3 Global Drugs for Metabolic Disorders Players Sales Volume Ranking (2023)
2.4 Global Drugs for Metabolic Disorders Sales Volume by Company Players (2019-2024)
2.5 Global Drugs for Metabolic Disorders Average Price by Company (2019-2024)
2.6 Key Manufacturers Drugs for Metabolic Disorders Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Drugs for Metabolic Disorders Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Drugs for Metabolic Disorders
2.9 Drugs for Metabolic Disorders Market Competitive Analysis
2.9.1 Drugs for Metabolic Disorders Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Drugs for Metabolic Disorders Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Metabolic Disorders as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Glycogen Metabolism Disease Drug
3.1.2 Lipid Metabolism Disease Drug
3.1.3 Amino Acid Metabolism Drug
3.1.4 Other
3.2 Global Drugs for Metabolic Disorders Sales Value by Type
3.2.1 Global Drugs for Metabolic Disorders Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Drugs for Metabolic Disorders Sales Value, by Type (2019-2030)
3.2.3 Global Drugs for Metabolic Disorders Sales Value, by Type (%) (2019-2030)
3.3 Global Drugs for Metabolic Disorders Sales Volume by Type
3.3.1 Global Drugs for Metabolic Disorders Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Drugs for Metabolic Disorders Sales Volume, by Type (2019-2030)
3.3.3 Global Drugs for Metabolic Disorders Sales Volume, by Type (%) (2019-2030)
3.4 Global Drugs for Metabolic Disorders Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.2 Global Drugs for Metabolic Disorders Sales Value by Application
4.2.1 Global Drugs for Metabolic Disorders Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Drugs for Metabolic Disorders Sales Value, by Application (2019-2030)
4.2.3 Global Drugs for Metabolic Disorders Sales Value, by Application (%) (2019-2030)
4.3 Global Drugs for Metabolic Disorders Sales Volume by Application
4.3.1 Global Drugs for Metabolic Disorders Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Drugs for Metabolic Disorders Sales Volume, by Application (2019-2030)
4.3.3 Global Drugs for Metabolic Disorders Sales Volume, by Application (%) (2019-2030)
4.4 Global Drugs for Metabolic Disorders Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Drugs for Metabolic Disorders Sales Value by Region
5.1.1 Global Drugs for Metabolic Disorders Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Drugs for Metabolic Disorders Sales Value by Region (2019-2024)
5.1.3 Global Drugs for Metabolic Disorders Sales Value by Region (2025-2030)
5.1.4 Global Drugs for Metabolic Disorders Sales Value by Region (%), (2019-2030)
5.2 Global Drugs for Metabolic Disorders Sales Volume by Region
5.2.1 Global Drugs for Metabolic Disorders Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Drugs for Metabolic Disorders Sales Volume by Region (2019-2024)
5.2.3 Global Drugs for Metabolic Disorders Sales Volume by Region (2025-2030)
5.2.4 Global Drugs for Metabolic Disorders Sales Volume by Region (%), (2019-2030)
5.3 Global Drugs for Metabolic Disorders Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Drugs for Metabolic Disorders Sales Value, 2019-2030
5.4.2 North America Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Drugs for Metabolic Disorders Sales Value, 2019-2030
5.5.2 Europe Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Drugs for Metabolic Disorders Sales Value, 2019-2030
5.6.2 Asia Pacific Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Drugs for Metabolic Disorders Sales Value, 2019-2030
5.7.2 South America Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Drugs for Metabolic Disorders Sales Value, 2019-2030
5.8.2 Middle East & Africa Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drugs for Metabolic Disorders Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Drugs for Metabolic Disorders Sales Value
6.2.1 Key Countries/Regions Drugs for Metabolic Disorders Sales Value, 2019-2030
6.2.2 Key Countries/Regions Drugs for Metabolic Disorders Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Drugs for Metabolic Disorders Sales Value, 2019-2030
6.3.2 United States Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Drugs for Metabolic Disorders Sales Value, 2019-2030
6.4.2 Europe Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Drugs for Metabolic Disorders Sales Value, 2019-2030
6.5.2 China Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.5.3 China Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Drugs for Metabolic Disorders Sales Value, 2019-2030
6.6.2 Japan Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Drugs for Metabolic Disorders Sales Value, 2019-2030
6.7.2 South Korea Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Drugs for Metabolic Disorders Sales Value, 2019-2030
6.8.2 Southeast Asia Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Drugs for Metabolic Disorders Sales Value, 2019-2030
6.9.2 India Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
6.9.3 India Drugs for Metabolic Disorders Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Drugs for Metabolic Disorders Product Offerings
7.1.5 Merck Recent Development
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Drugs for Metabolic Disorders Product Offerings
7.2.5 Novartis Recent Development
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Information
7.3.2 Takeda Pharmaceutical Introduction and Business Overview
7.3.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Product Offerings
7.3.5 Takeda Pharmaceutical Recent Development
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Information
7.4.2 Astra Zeneca Introduction and Business Overview
7.4.3 Astra Zeneca Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Astra Zeneca Drugs for Metabolic Disorders Product Offerings
7.4.5 Astra Zeneca Recent Development
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Information
7.5.2 Boehringer Ingelheim Introduction and Business Overview
7.5.3 Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Boehringer Ingelheim Drugs for Metabolic Disorders Product Offerings
7.5.5 Boehringer Ingelheim Recent Development
7.6 KOWA
7.6.1 KOWA Company Information
7.6.2 KOWA Introduction and Business Overview
7.6.3 KOWA Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.6.4 KOWA Drugs for Metabolic Disorders Product Offerings
7.6.5 KOWA Recent Development
7.7 Kythera
7.7.1 Kythera Company Information
7.7.2 Kythera Introduction and Business Overview
7.7.3 Kythera Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Kythera Drugs for Metabolic Disorders Product Offerings
7.7.5 Kythera Recent Development
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Information
7.8.2 Fuji yakuhin Introduction and Business Overview
7.8.3 Fuji yakuhin Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Fuji yakuhin Drugs for Metabolic Disorders Product Offerings
7.8.5 Fuji yakuhin Recent Development
7.9 LG Life Science
7.9.1 LG Life Science Company Information
7.9.2 LG Life Science Introduction and Business Overview
7.9.3 LG Life Science Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.9.4 LG Life Science Drugs for Metabolic Disorders Product Offerings
7.9.5 LG Life Science Recent Development
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Information
7.10.2 Metsubishi Tanabe Pharma Introduction and Business Overview
7.10.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Offerings
7.10.5 Metsubishi Tanabe Pharma Recent Development
8 Industry Chain Analysis
8.1 Drugs for Metabolic Disorders Industrial Chain
8.2 Drugs for Metabolic Disorders Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drugs for Metabolic Disorders Sales Model
8.5.2 Sales Channel
8.5.3 Drugs for Metabolic Disorders Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
Kowa
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
List of Tables
    Table 1. Drugs for Metabolic Disorders Market Trends
    Table 2. Drugs for Metabolic Disorders Market Drivers & Opportunity
    Table 3. Drugs for Metabolic Disorders Market Challenges
    Table 4. Drugs for Metabolic Disorders Market Restraints
    Table 5. Global Drugs for Metabolic Disorders Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Drugs for Metabolic Disorders Revenue Market Share by Company (2019-2024)
    Table 7. Global Drugs for Metabolic Disorders Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Drugs for Metabolic Disorders Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Drugs for Metabolic Disorders Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Drugs for Metabolic Disorders Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Drugs for Metabolic Disorders Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Drugs for Metabolic Disorders
    Table 13. Global Drugs for Metabolic Disorders Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Metabolic Disorders as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Drugs for Metabolic Disorders Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Drugs for Metabolic Disorders Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Drugs for Metabolic Disorders Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Drugs for Metabolic Disorders Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Drugs for Metabolic Disorders Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Drugs for Metabolic Disorders Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Drugs for Metabolic Disorders Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Drugs for Metabolic Disorders Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Drugs for Metabolic Disorders Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Drugs for Metabolic Disorders Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Drugs for Metabolic Disorders Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Drugs for Metabolic Disorders Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Drugs for Metabolic Disorders Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Drugs for Metabolic Disorders Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Drugs for Metabolic Disorders Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Drugs for Metabolic Disorders Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Drugs for Metabolic Disorders Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Drugs for Metabolic Disorders Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Drugs for Metabolic Disorders Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Drugs for Metabolic Disorders Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Drugs for Metabolic Disorders Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Drugs for Metabolic Disorders Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Drugs for Metabolic Disorders Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Drugs for Metabolic Disorders Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Drugs for Metabolic Disorders Sales Value by Region (2019-2024) & (%)
    Table 44. Global Drugs for Metabolic Disorders Sales Value by Region (2025-2030) & (%)
    Table 45. Global Drugs for Metabolic Disorders Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Drugs for Metabolic Disorders Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Drugs for Metabolic Disorders Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Drugs for Metabolic Disorders Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Drugs for Metabolic Disorders Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Drugs for Metabolic Disorders Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Drugs for Metabolic Disorders Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Drugs for Metabolic Disorders Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Drugs for Metabolic Disorders Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Drugs for Metabolic Disorders Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Drugs for Metabolic Disorders Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Drugs for Metabolic Disorders Sales Volume, (2025-2030) & (K Units)
    Table 57. Merck Company Information
    Table 58. Merck Introduction and Business Overview
    Table 59. Merck Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Merck Drugs for Metabolic Disorders Product Offerings
    Table 61. Merck Recent Development
    Table 62. Novartis Company Information
    Table 63. Novartis Introduction and Business Overview
    Table 64. Novartis Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Novartis Drugs for Metabolic Disorders Product Offerings
    Table 66. Novartis Recent Development
    Table 67. Takeda Pharmaceutical Company Information
    Table 68. Takeda Pharmaceutical Introduction and Business Overview
    Table 69. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. Takeda Pharmaceutical Drugs for Metabolic Disorders Product Offerings
    Table 71. Takeda Pharmaceutical Recent Development
    Table 72. Astra Zeneca Company Information
    Table 73. Astra Zeneca Introduction and Business Overview
    Table 74. Astra Zeneca Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Astra Zeneca Drugs for Metabolic Disorders Product Offerings
    Table 76. Astra Zeneca Recent Development
    Table 77. Boehringer Ingelheim Company Information
    Table 78. Boehringer Ingelheim Introduction and Business Overview
    Table 79. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Boehringer Ingelheim Drugs for Metabolic Disorders Product Offerings
    Table 81. Boehringer Ingelheim Recent Development
    Table 82. KOWA Company Information
    Table 83. KOWA Introduction and Business Overview
    Table 84. KOWA Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. KOWA Drugs for Metabolic Disorders Product Offerings
    Table 86. KOWA Recent Development
    Table 87. Kythera Company Information
    Table 88. Kythera Introduction and Business Overview
    Table 89. Kythera Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Kythera Drugs for Metabolic Disorders Product Offerings
    Table 91. Kythera Recent Development
    Table 92. Fuji yakuhin Company Information
    Table 93. Fuji yakuhin Introduction and Business Overview
    Table 94. Fuji yakuhin Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Fuji yakuhin Drugs for Metabolic Disorders Product Offerings
    Table 96. Fuji yakuhin Recent Development
    Table 97. LG Life Science Company Information
    Table 98. LG Life Science Introduction and Business Overview
    Table 99. LG Life Science Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. LG Life Science Drugs for Metabolic Disorders Product Offerings
    Table 101. LG Life Science Recent Development
    Table 102. Metsubishi Tanabe Pharma Company Information
    Table 103. Metsubishi Tanabe Pharma Introduction and Business Overview
    Table 104. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Offerings
    Table 106. Metsubishi Tanabe Pharma Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Drugs for Metabolic Disorders Downstream Customers
    Table 110. Drugs for Metabolic Disorders Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Drugs for Metabolic Disorders Product Picture
    Figure 2. Global Drugs for Metabolic Disorders Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Drugs for Metabolic Disorders Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Drugs for Metabolic Disorders Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Drugs for Metabolic Disorders Report Years Considered
    Figure 7. Global Drugs for Metabolic Disorders Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Drugs for Metabolic Disorders Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Metabolic Disorders Revenue in 2023
    Figure 10. Drugs for Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Glycogen Metabolism Disease Drug Picture
    Figure 12. Lipid Metabolism Disease Drug Picture
    Figure 13. Amino Acid Metabolism Drug Picture
    Figure 14. Other Picture
    Figure 15. Global Drugs for Metabolic Disorders Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Drugs for Metabolic Disorders Sales Value Market Share by Type, 2023 & 2030
    Figure 17. Global Drugs for Metabolic Disorders Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 18. Global Drugs for Metabolic Disorders Sales Volume Market Share by Type, 2023 & 2030
    Figure 19. Global Drugs for Metabolic Disorders Price by Type (2019-2030) & (USD/Unit)
    Figure 20. Product Picture of Hospital
    Figure 21. Product Picture of Retail Pharmacy
    Figure 22. Global Drugs for Metabolic Disorders Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Drugs for Metabolic Disorders Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Drugs for Metabolic Disorders Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Drugs for Metabolic Disorders Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Drugs for Metabolic Disorders Price by Application (2019-2030) & (USD/Unit)
    Figure 27. North America Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Drugs for Metabolic Disorders Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Drugs for Metabolic Disorders Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Drugs for Metabolic Disorders Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Drugs for Metabolic Disorders Sales Volume (%), (2019-2030)
    Figure 39. United States Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Drugs for Metabolic Disorders Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Drugs for Metabolic Disorders Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Drugs for Metabolic Disorders Sales Value by Application (%), 2023 VS 2030
    Figure 60. Drugs for Metabolic Disorders Industrial Chain
    Figure 61. Drugs for Metabolic Disorders Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Metabolic Disorders Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Metabolic Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metabolism Drugs Market Research Report 2025
Metabolic Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metabolic Disease Drugs Market Research Report 2025
Global Metabolic Disease Therapeutics Market Research Report 2025
Drugs for Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Treating Metabolic Disorders Market Research Report 2024
Lipid Metabolism Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lipid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Glycogen Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Amino Acid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Amino Acid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Amino Acid Metabolism Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Amino Acid Metabolism Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Bone Metabolism Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions